Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Inv. presentation
Quarterly results
Appointed director
|
|
ARGOS THERAPEUTICS INC (ARGS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/03/2019 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits |
| 12/03/2018 |
8-K
| Resignation/termination of a director |
| 07/20/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/24/2018 |
8-K
| Quarterly results |
| 04/19/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/02/2018 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights DURHAM, NC, April 02, 2018 -- Argos Therapeutics, Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision immunotherapy technology platform, today reported financial results and operational highlights for the fourth quarter and full year 2017. Jeff Abbey, CEO of Argos Therapeutics, stated, "Although we faced a very challenging 2017, we have been able to continue the Phase 3 ADAPT clinical trial of Rocapuldencel-T for the treatment of metastatic renal cell carcinoma, and look forward to the next interim data analysis, which we expect to occur during the second quarter of 2018. In addition to cont..." |
|
| 03/07/2018 |
8-K
| Other Events |
| 02/16/2018 |
8-K
| Quarterly results |
| 02/05/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Amended and Restated Sales Agreement, by and between the Company and Cowen and Company, LLC",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Argos Obtains Option to License PD1 Checkpoint Inhibitors - Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on Tuesday, February 6, 2018 at 8:30 a.m. ET - DURHAM, N.C., Feb. 05, 2018 -- Argos Therapeutics Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it has entered into an option agreement with Pharmstandard International, S.A. and Actigen Limited under which the Company has an option to license a group of fully human anti-PD1 monoclonal antibodies and related technology. Results of a preclinic..." |
|
| 01/30/2018 |
8-K/A
| Financial Statements and Exhibits |
| 01/18/2018 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 01/08/2018 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"Argos Announces $1.5 Million Equity Investment by Lummy , Ltd. DURHAM, N.C., Jan. 08, 2018 -- Argos Therapeutics Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it has signed a stock purchase agreement with Lummy , Ltd. , the Company’s partner for Rocapuldencel-T in China and certain other territories, under which the Company has agreed to issue and sell to Lummy in a private financing 7.5 million shares of the Company’s common stock for an aggregate purchase price of $1.5 million. The sale of the shares is expected to close on or prior to March 7, 2018. Lummy has agreed that, on the closing date, it will execute and deliver a lockup a..." |
|
| 11/28/2017 |
8-K
| Asset disposition|
Docs:
|
"Satisfaction and Release Agreement, by and between the Company and Saint-Gobain Performance Plastics Corporation, including a form of the Convertible Unsecured Promissory Note to be issued by the Company",
"Registration Rights Agreement, by and between the Company and Saint-Gobain Performance Plastics Corporation",
"Argos Provides Financial Update DURHAM, N.C., Nov. 28, 2017 -- Argos Therapeutics Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that TKC Properties, the landlord of the facility in Durham County, NC that Argos had previously intended to utilize as its primary manufacturing facility , has, with Argos’ full consent, successfully completed the sale of this facility to a third party. In connection with this transaction, Argos has entered into a lease termination agreement with TKC pursuant to which Argos received cash proceeds of approximately $1.8 million. Additionally, Argos is no longer required to maintain restricted cash of approximately..." |
|
| 11/09/2017 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 11/06/2017 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 10/27/2017 |
8-K
| Quarterly results |
| 09/26/2017 |
8-K
| Quarterly results |
| 09/25/2017 |
8-K
| Quarterly results |
| 09/12/2017 |
8-K
| Quarterly results |
| 09/05/2017 |
8-K
| Quarterly results |
| 08/02/2017 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/16/2017 |
8-K
| Form 8-K - Current report |
| 05/04/2017 |
8-K
| Form 8-K - Current report |
| 04/18/2017 |
8-K
| Form 8-K - Current report |
| 04/13/2017 |
8-K
| Other Events |
| 04/04/2017 |
8-K
| Form 8-K - Current report |
| 03/23/2017 |
8-K
| Termination of a Material Definitive Agreement |
| 03/09/2017 |
8-K
| Form 8-K - Current report |
| 03/06/2017 |
8-K
| Form 8-K - Current report |
| 02/22/2017 |
8-K
| Form 8-K - Current report |
| 01/23/2017 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 12/15/2016 |
8-K
| Form 8-K - Current report |
| 11/14/2016 |
8-K
| Quarterly results |
| 08/10/2016 |
8-K
| Form 8-K - Current report |
|
|
|